We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
Cap. Flow
+$195M
Cap. Flow %
9.6%
Top 10 Hldgs %
52.83%
Holding
78
New
7
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$101M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.1M
3
RVMD icon
Revolution Medicines
RVMD
+$17.2M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.2M
5
ELVN icon
Enliven Therapeutics
ELVN
+$14.5M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$19.6M
2
ARVN icon
Arvinas
ARVN
+$5.13M
3
FATE icon
Fate Therapeutics
FATE
+$4.53M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$638K
5
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$204M 10%
1,897,500
– –
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$112M 5.49%
1,230,004
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$108M 5.29%
500,000
– –
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.57B
$107M 5.25%
+775,000
New +$101M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$104M 5.11%
1,576,000
– –
TYRA icon
6
Tyra Biosciences
TYRA
$1.9B
$104M 5.09%
6,448,359
– –
RVMD icon
7
Revolution Medicines
RVMD
$39.9B
$101M 4.98%
4,684,264
+700,000
+18% +$17.2M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$88.1M 4.33%
3,421,541
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$74.4M 3.65%
2,000,000
– –
CYTK icon
10
Cytokinetics
CYTK
$10.5B
$73.9M 3.63%
2,100,000
– –
AMLX icon
11
Amylyx Pharmaceuticals
AMLX
$2.26B
$61.1M 3%
2,084,000
– –
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$45.9M 2.26%
1,094,000
– –
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$40.5M 1.99%
+200,000
New +$32.1M
RLAY icon
14
Relay Therapeutics
RLAY
$4.1B
$35.7M 1.76%
2,169,132
– –
MRUS
15
DELISTED
Merus
MRUS
$35M 1.72%
1,900,000
– –
VKTX icon
16
Viking Therapeutics
VKTX
$3.7B
$33.3M 1.64%
2,000,000
+500,000
+33% +$5.16M
ETNB
17
DELISTED
89bio
ETNB
$32M 1.57%
2,100,000
+700,000
+50% +$9.13M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$31.8M 1.56%
831,495
– –
NUVL
19
DELISTED
Nuvalent
NUVL
$31.6M 1.55%
1,210,192
– –
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.42B
$30.2M 1.49%
2,202,812
– –
ITOS
21
DELISTED
iTeos Therapeutics
ITOS
$29.3M 1.44%
2,154,058
– –
VTYX
22
DELISTED
Ventyx Biosciences
VTYX
$28.5M 1.4%
850,000
– –
ANAB icon
23
AnaptysBio
ANAB
$1.58B
$28.3M 1.39%
1,300,000
– –
TNGX icon
24
Tango Therapeutics
TNGX
$4.43B
$28.1M 1.38%
7,123,642
– –
RCUS icon
25
Arcus Biosciences
RCUS
$3.55B
$26.1M 1.28%
1,432,200
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Boxer Capital held 78 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Boxer Capital deployed $195M of net new capital in Q1 2023, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 775,000 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $4.53M trimmed.

  • Boxer Capital's largest Q1 2023 buy was Sarepta Therapeutics: 775,000 shares worth $107M.
  • Boxer Capital added most to Revolution Medicines in Q1 2023, an estimated $17.2M increase.
  • Boxer Capital's biggest Q1 2023 reduction was Fate Therapeutics, cutting an estimated $4.53M.
  • Boxer Capital fully exited Geron in Q1 2023, selling an estimated $19.6M.
  • Boxer Capital's ten largest holdings make up 53% of its $2.04B portfolio in Q1 2023.
  • Boxer Capital opened 7 new positions and closed 3 in Q1 2023.
  • Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.

Based on Boxer Capital's 13F filing for Q1 2023, filed 15 May 2023.